VYVANSE CAPSULE

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

LISDEXAMFETAMINE DIMESYLATE

Dostupné s:

TAKEDA CANADA INC

ATC kód:

N06BA12

INN (Mezinárodní Name):

LISDEXAMFETAMINE

Dávkování:

50MG

Léková forma:

CAPSULE

Složení:

LISDEXAMFETAMINE DIMESYLATE 50MG

Podání:

ORAL

Jednotky v balení:

100

Druh předpisu:

Schedule G (CDSA I)

Terapeutické oblasti:

AMPHETAMINES

Přehled produktů:

Active ingredient group (AIG) number: 0152536002; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2015-02-12

Charakteristika produktu

_VYVANSE_
_®_
_ (lisdexamfetamine dimesylate) _
_Page 1 of 67_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
VYVANSE®
lisdexamfetamine dimesylate capsules
Capsules, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg, oral
lisdexamfetamine dimesylate chewable tablets
Chewable Tablets, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg, oral
Central Nervous System Stimulant
Takeda Canada Inc.
22 Adelaide Street West, Suite 3800
Toronto, Ontario
M5H 4E3
Date of Initial Authorization:
19 February 2009
Date of Revision:
MAR 20, 2024
Submission Control Number: 280611
VYVANSE® and the VYVANSE Logo® are registered trademarks of Takeda
Pharmaceuticals U.S.A.,
Inc.
TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda
Pharmaceutical Company
Limited, used under license.
_VYVANSE_
_®_
_ (lisdexamfetamine dimesylate) _
_Page 2 of 67_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Cardiovascular, QTc Prolongation
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
5
1.2
Geriatrics
.................................................................................................................
6
2
CONTRAINDICATIONS
...................................................................................................
6
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................